Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 53

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 53
---
, the Company filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation (the “Certificate
of Incorporation”), to effect a change of the Company’s name from “Conduit Pharmaceuticals Inc.” to “CDT
Equity Inc.”, which became effective at 5:00 P.M. Eastern Time on August 5, 2025. The Company’s Common Stock continues to
be listed on The Nasdaq Capital Market under the ticker symbol “CDT”. In addition, the CUSIP number for the Common Stock
remains the same.

CDT
Equity Inc. Amended and Restated 2023 Stock Incentive Plan

On
August 5, 2025, at the Company’s 2025 Annual Meeting of Stockholders, stockholders approved an amendment and restatement of the
Company’s 2023 Stock Incentive Plan (as amended, the “Amended 2023 Stock Incentive Plan”) to authorize an additional
2,000,000 shares of Common Stock for awards under the Amended 2023 Stock Incentive Plan. The Amended 2023 Stock Incentive Plan was recommended
and approved by the Board on July 8, 2025.

Sarborg
- Additional Agreement Addendum 2

On
August 11, 2025 the Company entered into Addendum 2 to the Additional Agreement with Sarborg Limited, a related party. Under the terms
of Addendum 2, Sarborg will expand the scope of work and integrate a Cryptocurrency AI Agent, developed specifically for identifying,
forecasting and recommending digital currencies into CDT Equity’s Operations as part of its Treasury Strategy.

The Term of the Engagement
is for a minimum of four (4) months, which may be renewed or extended upon the mutual written agreement of the Parties. The initial consideration
for the Proposal for Expanded Scope of Work shall be $150,000, payable on execution of this Agreement. Conduit agrees to pay a further
consideration of $150,000 in cash or shares (at CDT Equity’s sole discretion) at such time as CDT Equity invests more than $600,000
in cryptocurrency as part of its Treasury Strategy.

Sarborg
is a related party, Dr. Andrew Regan, Chief Executive Officer and member of the Board, also sits on the board of directors of Sarborg
but does not have an equity interest in Sarborg.

30

Item
2